CIDP, rituximab, COVID-19 infection

We would like to present a case report of a patient with post-COVID-19 development of acute-onset chronic infl ammatory demyelinating polyneuropathy (CIDP). According to the latest 2021 revision of the European guidelines, CIDP is divided into the typical CIDP and CIDP variants. The typical CIDP is characterized by a progressive or relapsing symmetrical proximal and distal muscle weakness of upper and lower limbs with progression for more than 8 weeks, sensory loss, and reduction or absence of tendon refl exes. About 13% of patients may develop an acute-onset CIDP (A-CIDP); in this case, it is diffi cult to distinguish from Guillain-Barré syndrome (GBS) [1].